Key Drivers
- Margin Strength
- High Leverage
- Cash Volatility
AIAI Summary
MNKD now looks more like a broader, evidence-backed platform story than a pure Afrezza one-product bet, but the investment remains highly execution-dependent because rising expenses, weak cash conversion, and heavy leverage mean the stock is priced for adoption that still has to be proven.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •High Leverage
- •Cash Volatility
MNKD shows strong gross margins and manageable near-term liquidity, but heavy leverage, negative equity, and weak quarter-to-quarter cash generation keep overall financial risk elevated.
Price Behavior
Key Price Behavior Insights:
- •Breakout Hold
- •Higher Lows
- •Pullback Risk
MNKD has stayed in a constructive uptrend over the last month, holding above $4.00 after breaking out near $4.26, though the rally looks stretched and could pull back toward $3.84-$3.93.
Sharp drop from $4.26 to $4.05 before rebounding, signaling near-term volatility risk
Sentiment & News
Key News Insights:
- •Pediatric expansion
- •Trial funding
- •Broader evidence
MNKD is building momentum for Afrezza by expanding clinical evidence in pediatrics, pregnancy, and automated insulin delivery, highlighted by a Breakthrough T1D grant for its youth T1D trial.
This news is modestly positive for MNKD as it strengthens Afrezza's credibility and expands its addressable clinical use cases, especially in younger patients
Similar Companies in Healthcare
Other companies in the same sector with AI ratings